Pacira BioSciences (PCRX)
(Delayed Data from NSDQ)
$16.52 USD
+0.63 (3.93%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $16.52 +0.01 (0.03%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum A VGM
Price, Consensus and EPS Surprise
PCRX 16.52 +0.63(3.93%)
Will PCRX be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for PCRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for PCRX
Pacira's Exparel Receives Permanent New Product-Specific J-Code
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
PCRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Pacira (PCRX) Down 27.9% Since Last Earnings Report: Can It Rebound?
Pacira (PCRX) Plummets as US Court Deems Exparel Patent Invalid
Other News for PCRX
PharmaCorp Expands with Atlantic Canada Pharmacy Acquisition
Pacira receives Medicare permanent J-code for Exparel
Pacira announces product-specific J-Code for EXPAREL effective Jan. 1
Pacira completes acquisition of pharmacy business in Atlantic Canada
Executive reshuffles: NSC, PCRX and OMI Companies in focus